medwireNews: ASCO and Ontario Health (Cancer Care Ontario [CCO]) have issued updated recommendations for the adjuvant use of bone-modifying agents in people with breast cancer.
The guideline updates the previous version issued in 2017 by ASCO–CCO, focusing especially on patient selection, the choice and dose of bisphosphonates, and the use of denosumab.
“The remaining recommendations from the 2017 guideline are unchanged because there were no new potentially practice-changing data to support substantive revisions,” write the guideline authors in the Journal of Clinical Oncology.
The resource was developed by a joint ASCO–Ontario Health multidisciplinary expert panel, and relies on data from four randomized controlled trials published since 2017 – namely SWOG S0307, ABCSG-18, D-CARE, and SUCCESS A – for the revised recommendations.
“This guideline should be used in conjunction with the Multinational Association of Supportive Care in Cancer-International Society of Oral Oncology-ASCO guideline on medication-related [osteonecrosis of the jaw],” say the authors.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group